Estrella Immunopharma, Inc. (ESLAW) company profile

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company that develops engineered T-cell therapies for individuals with hematologic cancers, solid tumors, and autoimmune diseases. Its therapeutic programs utilize a proprietary receptor platform designed to regulate T-cell activation. The company's lead product candidate, EB103, targets CD19 and is under clinical evaluation for patients with relapsed or refractory B-cell non-Hodgkin lymphoma, particularly those ineligible for existing treatments. Additionally, the company develops EB104, a dual-targeting therapy directed against CD19 and CD22 for blood cancers, and EB201, a preclinical program targeting systemic lupus erythematosus. Its primary end users are patients suffering from severe malignancies and immune disorders.

The company is headquartered in Emeryville, California, and maintains a wholly owned subsidiary in Hong Kong. Its ongoing clinical operations are based in the United States, with active study sites located at research facilities in California and Texas. The business holds development and commercialization rights across worldwide territories, excluding Greater China and member countries of the Association of Southeast Asian Nations.

Summary of the business section of Estrella Immunopharma's latest annual report, written by StockData.

“Each unit has an offering price of $10.00 and consists of one share of our common stock and one-half of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.